U.S. pharma big copyright scrapped two experimental weight loss products previous year—a at the time-daily capsule, lotiglipron, as a result of elevated liver enzymes and a 2 times-everyday pill, danuglipron, on account of strong Unwanted effects—but CEO Albert Bourla has claimed the company is set to “play and gain” from the being overweig